Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy

World Journal of Gastroenterology

Volumn 7, Issue 1, 2001, Pages 22-27

  Tang, Y C ^a   Li, Y ^a   Qian, G X ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; DNA FRAGMENT; MESSENGER RNA; VASCULOTROPIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CARCINOGENICITY; CELL CLONE; CONTROLLED STUDY; DNA INTEGRATION; GENE CASSETTE; GENE CONSTRUCT; GENE INSERTION; GENE THERAPY; GENETIC TRANSDUCTION; HEPATOMA CELL; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; NONHUMAN; NUDE MOUSE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; RESTRICTION MAPPING; REVERSE TRANSCRIPTION; RIBONUCLEASE PROTECTION ASSAY; SOUTHERN BLOTTING; TRANSGENE; VIRUS REPLICATION;

EID: 0035109957     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v7.i1.22     Document Type: Article

References (52)

1. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
2. Angiogenesis in cancer and other diseases
3. In vivo assessment of vascular endothelial growth factor-induced angiogenesis
4. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
5. 121
6. Angiogenesis and apoptosis in human hepatocellular carcinoma
7. Relationship between microvessel density and proliferating cell nuclear antigen and prognosis in colorectal cancer
8. Relationship between proliferation of vascular endothelial cells and gastric cancer
9. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
10. Intratumor microvessel density as a prognostic factor in cancer
11. The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts
12. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
13. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
14. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
15. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
16. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis
17. Vascular endothelial growth factor stimulates dephosphorylation of the catenins p120 and p100 in endothelial cells
18. Vascular endothelial growth factor (VEGF) and its receptors
19. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
20. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
21. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
22. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
23. Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed Hep G2 cells
24. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
25. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma
26. Study of angiogenesis induced by metastatic and non-metastatic liver cancer by corneal micropocket model in nude mice
27. Expression of vascular endothelial growth factor in human hepatocellular carcinoma
28. New concept in etiology of liver cancer
29. 3 protein on P53 expression in hepatocarcinogenesis
30. Apoptosis, Bcl-2 and P53 protein expressions in tissues from hepatocellular carcinoma
31. Relationship between ras p53 gene RNA and protein expression and HCC metastasis
32. Relationship between EBV infection in Fujian HCC and HBV and P53 protein expression
33. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
34. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions
35. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
36. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
37. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
38. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker
39. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma
40. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line
41. Killing effect of DT/VEGF system on gastric carcinoma cell
42. Killing effect of tetracycline-controlled expression of DT/VEGF system on liver cell cancer
43. Effects of angiogenesis inhibitor TNP - 470 with lipiodol in arterial embolization of liver cancer in rabbit model
44. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
45. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
46. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
47. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
48. Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter
49. Cis-acting elements required for RNA polymerase II and III transcription in the human U2 and U6 snRNA promoters
50. Sites of RNA polymerase III transcription initiation and Ty3 integration at the U6 gene are positioned by the TATA box
51. The transcriptional start site for a human U6 small nuclear RNA gene is dictated by a compound promoter element consisting of the PSE and the TATA box
52. Expression of small, therapeutic RNAs in human cell nuclei